Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology

Standard of Care and Treatment Options

At a Glance

Narcolepsy Type 1 is treated with a combination of medications targeting both excessive daytime sleepiness and cataplexy. Treatment plans often combine daytime wake-promoting agents with nighttime sleep-stabilizing medications to safely improve daily functioning and quality of life.

Managing Narcolepsy Type 1 (NT1) often requires a multi-faceted approach. Because NT1 affects both your ability to stay awake during the day and your muscle control during emotional moments, treatment plans are typically tailored to address both excessive daytime sleepiness (EDS) and cataplexy [1][2].

Targeting Sleepiness (EDS)

Several medications are designed specifically to boost wakefulness. These do not usually treat cataplexy directly, but they can significantly improve your ability to function throughout the day:

  • Traditional Stimulants: Medications like methylphenidate or amphetamines have been used for decades to increase alertness by increasing certain chemicals (like dopamine) in the brain [3][4]. While effective, they can cause cardiovascular side effects, such as increased heart rate or blood pressure, as well as feelings of anxiety or jitteriness [3].
  • Wake-Promoting Agents: Modafinil and armodafinil are often first-line choices because they tend to have fewer side effects than traditional stimulants [5][6].
  • Solriamfetol: This is a newer medication that works on both dopamine and norepinephrine to keep you awake. It is specifically approved for EDS but does not treat cataplexy [7].

Important Safety Note: Medications like modafinil, armodafinil, and pitolisant can significantly reduce the effectiveness of hormonal birth control. Patients on these medications must use alternative, non-hormonal contraception to prevent unintended pregnancy [5][8].

Treating Both Sleepiness and Cataplexy

Some medications are “dual-action,” meaning they help you stay awake during the day and reduce the number of cataplexy episodes you experience:

  • Sodium Oxybate (and Low-Sodium Oxybate): These are taken at night. They work by improving the quality of your nighttime sleep, which paradoxically leads to better wakefulness during the day and a significant reduction in cataplexy [9][10].
    • Black-Box Warning: Because they are powerful Central Nervous System (CNS) depressants, they carry a black-box warning for severe respiratory depression [9]. They must never be combined with alcohol or other sedating medications, as this combination can be fatal [9]. They are only available through restricted distribution programs [11].
  • Pitolisant: This is a newer, non-stimulant medication taken once in the morning. It works by increasing histamine—a natural “wake-up” chemical—in the brain [12]. It is approved to treat both EDS and cataplexy [8][13].

Off-Label and Emerging Options

In addition to FDA-approved treatments, doctors may use other strategies:

  • SSRIs and SNRIs: While not specifically approved for narcolepsy, certain antidepressants (like venlafaxine) are often used off-label (using a drug for a purpose other than its official approval) to treat cataplexy [14]. They work by suppressing the REM-sleep signals that cause muscle weakness [15][16].
  • The Future: Orexin Agonists: Because NT1 is caused by a lack of hypocretin (orexin), researchers are developing “orexin receptor agonists” [17]. These experimental drugs aim to replace the missing chemical directly. While early results are promising in reducing both sleepiness and cataplexy, many are still in clinical trials to ensure they are safe for the liver and other organs [18][19].

A Combined Approach

Many patients find the most success with a multi-modal approach [20]. This might include a combination of a nighttime medication to stabilize sleep and a morning medication to provide an extra boost of alertness [2]. Your care team will work with you to balance the benefits of these treatments with any side effects to find the right “fit” for your life.

Common questions in this guide

How are excessive daytime sleepiness and cataplexy treated differently?
Some medications, like modafinil or solriamfetol, specifically target daytime sleepiness by boosting alertness. Other treatments, known as dual-action medications like sodium oxybate or pitolisant, can improve both daytime sleepiness and cataplexy at the same time.
Do narcolepsy medications interact with hormonal birth control?
Yes, certain wake-promoting medications for narcolepsy, including modafinil, armodafinil, and pitolisant, can significantly reduce the effectiveness of hormonal birth control. Patients on these medications must use alternative, non-hormonal contraception.
What is sodium oxybate and how does it help narcolepsy?
Sodium oxybate is a medication taken at night to improve nighttime sleep quality. Paradoxically, achieving better deep sleep at night leads to improved daytime wakefulness and a significant reduction in sudden muscle weakness, or cataplexy.
Can antidepressants be used to treat Narcolepsy Type 1?
Yes, while not officially approved for narcolepsy, certain antidepressants like SSRIs and SNRIs are frequently prescribed off-label. They help by suppressing the REM-sleep signals that trigger the sudden muscle weakness seen in cataplexy.
What are orexin agonists and how might they help narcolepsy?
Orexin receptor agonists are experimental drugs currently in clinical trials. Since Narcolepsy Type 1 is caused by a lack of the brain chemical hypocretin (orexin), these medications aim to address the root cause by directly replacing the missing chemical.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which of my symptoms—daytime sleepiness or cataplexy—should we prioritize with our first treatment choice?
  2. 2.Is sodium oxybate a good option for me given my nighttime sleep quality and current lifestyle?
  3. 3.If we use a medication like solriamfetol that only targets sleepiness, how will we manage my cataplexy?
  4. 4.What are the risks of using antidepressants off-label for cataplexy, and how do they compare to FDA-approved options like pitolisant?
  5. 5.Are there any clinical trials for orexin receptor agonists that I might be eligible for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Narcolepsy and Idiopathic Hypersomnia.

    Blattner M, Maski K

    Sleep medicine clinics 2023; (18(2)):183-199 doi:10.1016/j.jsmc.2023.01.003.

    PMID: 37120161
  2. 2

    Work productivity and activity impairment in patients with narcolepsy type 1.

    Bassi C, Biscarini F, Zenesini C, et al.

    Journal of sleep research 2024; (33(3)):e14087 doi:10.1111/jsr.14087.

    PMID: 38086564
  3. 3

    Resolution of Sleepwalking Behavior after Initiation of Sodium Oxybate in a Patient with Narcolepsy Type 2.

    Hesselbacher S, Sharafkhaneh A

    Cureus 2018; (10(5)):e2662 doi:10.7759/cureus.2662.

    PMID: 30042913
  4. 4

    Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion.

    Arnulf I, Thomas R, Roy A, Dauvilliers Y

    Sleep medicine reviews 2023; (69()):101766 doi:10.1016/j.smrv.2023.101766.

    PMID: 36921459
  5. 5

    Armodafinil as Monotherapy in Treating Narcolepsy with Cataplexy.

    Ahmed A, Tariq S, Khan SJ, Shah ZH

    Cureus 2024; (16(12)):e76437 doi:10.7759/cureus.76437.

    PMID: 39737109
  6. 6

    Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1.

    Schinkelshoek MS, Smolders IM, Donjacour CE, et al.

    Journal of sleep research 2019; (28(3)):e12684 doi:10.1111/jsr.12684.

    PMID: 29504180
  7. 7

    Pharmacological Interventions for Excessive Daytime Sleepiness in Adults with Narcolepsy: A Systematic Review and Network Meta-Analysis.

    Chien PY, Kuo CY, Lin MH, et al.

    Journal of clinical medicine 2022; (11(21)) doi:10.3390/jcm11216302.

    PMID: 36362535
  8. 8

    Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report.

    Pellitteri G, Dolso P, Valente M, Gigli GL

    Nature and science of sleep 2020; (12()):1237-1240 doi:10.2147/NSS.S286358.

    PMID: 33408544
  9. 9

    Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.

    Plazzi G, Ruoff C, Lecendreux M, et al.

    The Lancet. Child & adolescent health 2018; (2(7)):483-494 doi:10.1016/S2352-4642(18)30133-0.

    PMID: 30169321
  10. 10

    Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy.

    Abad VC

    Expert opinion on pharmacotherapy 2023; (24(8)):875-885 doi:10.1080/14656566.2023.2204187.

    PMID: 37060579
  11. 11

    The Xyrem® (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017.

    Strunc MJ, Black J, Lillaney P, et al.

    Drugs - real world outcomes 2021; (8(1)):15-28 doi:10.1007/s40801-020-00223-6.

    PMID: 33439474
  12. 12

    Multiple treatment comparison in narcolepsy: a network meta-analysis.

    Lehert P, Falissard B

    Sleep 2018; (41(12)) doi:10.1093/sleep/zsy185.

    PMID: 30239930
  13. 13

    Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study.

    Plazzi G, Mayer G, Bodenschatz R, et al.

    Sleep medicine 2025; (129()):20-30 doi:10.1016/j.sleep.2025.02.012.

    PMID: 39978240
  14. 14

    REM Sleep at its Core - Circuits, Neurotransmitters, and Pathophysiology.

    Fraigne JJ, Torontali ZA, Snow MB, Peever JH

    Frontiers in neurology 2015; (6()):123 doi:10.3389/fneur.2015.00123.

    PMID: 26074874
  15. 15

    Antidepressants for the treatment of narcolepsy: A prospective study of 148 patients in northern China.

    Jin L, Shi L, Zhang Y, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2019; (63()):27-31 doi:10.1016/j.jocn.2019.02.014.

    PMID: 30837110
  16. 16

    Serotonin neurons in the dorsal raphe mediate the anticataplectic action of orexin neurons by reducing amygdala activity.

    Hasegawa E, Maejima T, Yoshida T, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2017; (114(17)):E3526-E3535 doi:10.1073/pnas.1614552114.

    PMID: 28396432
  17. 17

    Recent insights into the pathophysiology of narcolepsy type 1.

    Vringer M, Zhou J, Gool JK, et al.

    Sleep medicine reviews 2024; (78()):101993 doi:10.1016/j.smrv.2024.101993.

    PMID: 39241492
  18. 18

    Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.

    Dauvilliers Y, Mignot E, Del Río Villegas R, et al.

    The New England journal of medicine 2023; (389(4)):309-321 doi:10.1056/NEJMoa2301940.

    PMID: 37494485
  19. 19

    An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions.

    Ishikawa T, Kurimoto E, Joyal AA, et al.

    Current biology : CB 2025; (35(9)):2088-2099.e4 doi:10.1016/j.cub.2025.03.040.

    PMID: 40233754
  20. 20

    Exploring the emotional and behavioural profile in paediatric narcolepsy type 1: A case-control study.

    Simoncini Malucelli G, Mercante A, Pizza F, et al.

    Journal of sleep research 2024; (33(4)):e14064 doi:10.1111/jsr.14064.

    PMID: 37872846

This page provides educational information about standard treatment options for Narcolepsy Type 1. Always consult your sleep specialist or neurologist to determine the safest and most effective medication plan for your specific symptoms and lifestyle.

Get notified when new evidence is published on Narcolepsy type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.